Background: Approximately 75% of all deaths in people with schizophrenia are caused by physical illness with cardiovascular disease [CVD] being the commonest cause of death. Factors predisposing people with schizophrenia to CVD include antipsychotic medication. Aim of Work: The aim of this study was to detect metabolic syndrome and its components in de novo paranoid schizophrenics on olanzapine therapy and the metabolic benefits of addition of aripeprazole, clinically and experimentally. Methodology: 1) Clinical study: 200 Outpatients suffered from de novo paranoid schizophrenia according to 10 th
Introduction
Schizophrenia is a psychotic illness that affects approximately 1% of the population. Mortality rates are increased two-to four-fold in people with schizophrenia and life expectancy is reduced by 10 -20 years [1] [2] [3] . Approximately 75% of all deaths in people with schizophrenia are caused by physical illness with cardiovascular disease being the commonest cause of death [1] .
Since their introduction in 1990, atypical antipsychotics [AAPs] have become the most common treatment for patients with a variety of psychotic disorders [4] . Atypical antipsychotics used for the treatment of schizophrenia offer significant advantages over conventional compounds, particularly because they are associated with fewer extrapyramidal symptoms than conventional antipsychotics [5] . However, compelling evidence indicates that the use of AAPs is related to potentially serious adverse metabolic effects, including obesity, dyslipidemia, hyperglycemia, and type 2 diabetes mellitus [6] [7] . These metabolic disturbances may lead to an increase in the risk of cardiovascular diseases [CVD] and premature mortality [8] .
Olanzapine is an atypical antipsychotic of the thienobenzodiazepine class. Although structurally and functionally related to clozapine, it possesses a more favourable side-effect profile [9] [10] . Recently, the scientists have tried to elucidate the mechanism of toxicities associated with olanzapine [11] . [18] for MetS are aimed at being easy to use in clinical settings and share similar diagnostic thresholds [19] . As a prevalent condition and predictor of CVD across racial, gender and age groups, MetS provides the opportunity to identify high-risk populations and prevent the progression of some major causes of morbidity and mortality [19] . Occupational Diseases and Environmental Medicine
Non-Alcoholic fatty liver disease [NAFLD] , is considered the hepatic manifestation of metabolic syndrome [MetS] [20] . NAFLD is common and has a spectrum of liver changes beginning with simple fatty liver and progressing to steatohepatitis, cirrhosis and liver failure. Alcoholic fatty liver disease [AFLD] is frequently present along with the components of metabolic syndrome and, hence, is generally regarded as a manifestation of metabolic syndrome [21] .
Non-alcoholic steatohepatitis [NASH] is recognized as a progressive form of fatty liver disease, has been documented to have the potential to progress to cirrhosis and hepatocellular carcinoma [21] [22] .
The aim of this study was to detect MetS and its components in people with de novo paranoid schizophrenia on olanzapine therapy. We aimed to assess the safety and the metabolic benefits of addition of aripeprazole to olanzapine treated patients suffered from metabolic syndrome. Experimentally, we aimed to investigate the metabolic effect of olanzapine and its hepatic effects in wister rats and the effect of adjunctive aripeprazole. 200 Outpatients suffered from de novo paranoid schizophrenia according to ICD10 RC [23] were included in the study after providing written informed consent. All subjects were maintained on olanzapine [10 -20 mg] . Patients had to be maintained on stable dose of olanzapine for at least 3 months. All patients had psycho-education program and their care givers concerning appropriate diet and physical activity for the patients.
Subject and Method

Clinical Study
Patients who had metabolic syndrome after 6 months of starting olanzapine therapy were randomly divided into two groups according to added regime to maintained olanzapine:
Group I: Olanzapine [10 mg/day] + placebo [prepared starch tablet similar in shape to aripiprazole tablet] Group II: Olanzapine [10 mg/day] +aripiprazole [10 mg/day] After three months, the two groups were subjected to assessment of all previous parameters.
Experimental Study
Ethical Consideration of Study
The experimental procedures and the use of laboratory animal were approved by the Animal Research Committee in Zagazig University. Painless procedures were conducted. Animal housing and handling were ethically considered.
Animals
The current study was performed using 40 [28] . Each tablet [10 mg], was dissolved in 10 ml normal saline, and each rat received 2 ml/kg/day of the dissolved drug via gastric tube [31] .
Group IV [combined olanzapine and aripiprazole treated]: received olanzapine at a dose of 0.5 mg/kg/day combined with aripiprazole at a dose of 2 mg/kg/day by gastric tube daily for 16 weeks.
The duration of the study was 16 weeks. Male rats were selected to obviate potential interactions with ovarian hormones previously found to influence primary outcome measures [32] [33] .
Body weight was recorded once weekly. By the end of the treatment period, animals were then fasted for 12 h and blood samples were withdrawn from the retro-orbital plexus for the Assessment of metabolic and biochemical parameters. Then all animals were scarified under light ether anathesia. The liver of each rat was removed and weighed then stained for histopathological studies. 
Assessment of Metabolic and Biochemical Parameters
Histopathological Examinations
 Liver slides for histopathological study were prepared and stained with routine hematoxylin and eosin staining [34] . Histological examination of liver in control group showed the maintenance of normal lobular architecture, normal histology ( Figure 1 ). Histopathological finding in olanzapine treated rat group (Figure 3 ) in the present study showed a picture of non-alcoholic liver disease in the form of ballooning degeneration, inflammatory infiltrates and accumulated lipid vacuoles in hepatocytes [steatosis]. Many Kupffer cells were also present. It had larger total fat cell areas than the control. There was no significant portal inflammation or hepatocytes damage at aripeprazole treated rats ( Figure 2 ). Combined olanzapine-and aripiprazole-treated rats (Figure 4) showed less prominent and less severe picture of non-alcoholic liver disease compared to olanzapine treated rats [the portal tract showed small aggregates of chronic inflammatory cells, fewer Kupffer cells, few fatty changes and ballooning degeneration]. experience a two-three times higher mortality rate than the general population [36] [37] . This mortality gap translates into a 10 -20-year shortened life expectancy [38] [39] and appears to be widening [40] . About 60% of the excess mortality observed in SMI is due to physical comorbidities, predominantly cardiovascular diseases [CVD] [41] . Factors predisposing people with SMI to CVD include antipsychotic medication and unhealthy lifestyles [42] as well as their reduced likelihood to receive standard levels of medical care [43] [44] [45] .
Statistical Analysis
Results
Clinical Results
Experimental Results
Body Weight and Liver Weight
Discussion
200 Outpatients suffered from de novo paranoid schizophrenia according to ICD10 RC [23] were included in the study. Few studies have included people with a first episode of psychosis and yet weight gain occurs commonly and rapidly in this group of individuals after treatment initiation. We have also specifically included people with first-episode psychosis, where the aim of the intervention may be the prevention of weight gain rather than weight loss [46] [47] . Several studies indicated that obesity is two to three times more prevalent among people with schizophrenia than in the general population and this occurs early in its natural history [48] .
After the 6 months of olanzapine treatment [mean dose 12.75 mg], there was significant increase in weight, body mass index, triglyceride, total cholesterol, and fasting blood glucose level compared to base line level of these parameters ( [50] . This is in line with many systematic reviews and meta-analyses which reported that olanzapine and clozapine induce most severe weight gain when compared with other antipsychotics [51] [52] [53] [54] .
Experimentally, Olanzapine treated rats had significantly more body weight and liver weight compared to other three studied groups, which was corresponding with previous reports [54] [55] [56] [57] [58] .
Weight gain is a common adverse effect of antipsychotic medication, affecting between 15% and 72% of patients [59] Most weight gain occurs early in treatment. Between 37% and 86% of those experiencing a first episode of psychosis also experiencing more than 7% weight gain in 12 months [60] , often occurring within 12 weeks of treatment initiation [61] .
In a trial to explain the mechanism of olanzapine-induced weight gain, several animal studies have found that olanzapine could modulate histaminergic neurotransmission for the regulation of food intake and weight gain in rats [62] [63] . Further evidence showed that weight gain and obesity associated with olanzapine are mediated by activation of the hypothalamic AMP-activated protein kinase [AMPK] pathway via blockade of H 1 receptors [64] [65] , and [66] . In fact, a recent study revealed an association between polymorphisms in the AMPK gene and weight gain induced by olanzapine and clozapine [67] . Additionally, it was reported that olanzapine down-regulates the anorexigenic neuropeptide proopiomelanocortin [POMC], but up-regulates the orexigenic neuropeptide Y [NPY], in the arcuate nuclei of the hypothalamus [Arc] [68] [69] There was significant increase in serum triglyceride level in olanzapine treated patients for 6 months. The main increase was 16 mg/dl. Olanzapine treated rats Occupational Diseases and Environmental Medicine in our study showed significant more triglyceride level than other studied groups.
Hypertriglyceridemia has been linked to olanzapine therapy [70] [71] . Atmaca et al. [72] observed a significant increase in weight and triglyceride levels in olanzapine-treated groups. Sheitman et al. [73] reported an increase in serum triglyceride from baseline to 16-month re-assessment where triglycerides increased more than 40%.
There is evidence that AAPs may cause hypertriglyceridemia through several possible mechanisms: 1) a direct effect on triglyceride metabolism either by stimulation of hepatic triglyceride production and secretion or by inhibition of lipoprotein lipase-mediated triglyceride hydrolysis and 2) an indirect mechanism associated with obesity and insulin resistance [74] . Olanzapine treated patients for 6 months demonstrated a main increase in fasting blood glucose [6.35 mg], cholesterol level [12.17 mg] and decrease in HDLC [5.12 mg]. Olanzapine treated rats in our study showed significant more fasting blood glucose, cholesterol level than other studied groups. Abnormalities of triglyceride and HDL metabolism are an early manifestation of insulin resistance, often detectable even before the development of abnormal postprandial or fasting glucose levels [75] .
It has been found that the metabolic disturbances associated with the use of atypical antipsychotics are a direct consequence of alteration of insulin sensitivity. Impaired parasympathetic regulation of β-cell activity mediated by blockade of histaminergic and muscarinic receptors may contribute to an increased metabolic risk [76] .
32 patients [16%] suffered from metabolic syndrome after 6 months of olanzapine therapy according to the recommendation of the International Diabetes Federation [IDF, 2009] Task Force on Epidemiology and Prevention [19] . MetS risk was significantly higher with clozapine, followed by olanzapine. [44] [77].
Olanzapine, can induce metabolic disturbances, such as obesity, hypertriglyceridemia, glucose dysregulation, and in some studies, elevated serum cholesterol levels [78] [79] . These metabolic disturbances may lead to an increase in the risk of cardiovascular diseases and premature mortality [8] . Despite these problems, the use of metabolically potent antipsychotic drugs is widespread, arguably due to superior therapeutic efficacy compared with antipsychotics with more favorable metabolic profiles [80] .
While switching to a more weight-neutral atypical antipsychotic agent offers promise in halting or reversing weight gain, many patients and their clinicians are reluctant to risk a worsening or return of psychotic symptoms and risk relapse [81] .
Experimentally, there was no significant difference between aripiprazole [ARI] treated group and control group as regards to metabolic changes in rats. This is in accordance with Greenaway and Elbe.'s review study [82] , in which they discussed 4 prospective randomized controlled trials and 9 open-label prospective studies about aripiprazole. They found that in all 4 randomized controlled trials, there was no significant increase in body weight. Occupational Diseases and Environmental Medicine ARI is associated with a lower risk of metabolic and cardiac issues such as weight gain, diabetes, and dyslipidemia than most SGAs [83] . Also, Sayyaparaju et al. [84] stated that aripiprazole was associated with minimal weight gain and metabolic changes [dyslipidemia, elevated serum triglycerides and impairments in glycemic control] unlike most second -generation antipsychotics.
The lowest MetS prevalence for aripiprazole is noteworthy, as antipsychotics with lower cardiometabolic risk profiles in short-term studies are often prescribed for higher risk patients in clinical care, which may lead to a not reduced or even increased cardiometabolic risk in naturalistic settings [85] .
After 3 months of aripiprazole, [10 mg/day], addition to maintained olanzapine therapy to patients suffered from metabolic syndrome, there was significant decrease in body weight, triglyceride, total cholesterol, and fasting blood glucose level compared to placebo-controlled group [maintained on olanzapine therapy]. Aripeprazole treatment did not significantly changed [SANS] [12.6 ± 1.01] and [SAPS] [10.03 ± 1.34] score. Combined olanzapine and aripiprazole treated rat group showed significant decrease in, body weight, liver weight, fasting blood Glucose, triglyceride, and cholesterol level when compared to olanzapine treated rats ( Table 3) .
Combined olanzapine and aripiprazole treated group showed significant decrease in body weight when compared to olanzapine treated group. Similar results were found by Henderson et al. [86] , who report the results of a 10-week placebo controlled, double-blind crossover study that examined 15 mg/day aripiprazole's effects upon multiple parameters including weight in overweight and obese schizophrenia and schizoaffective disorder subjects treated with a stable dose of olanzapine. They found that, subjects experienced significant reductions in weight after the addition of aripiprazole to a stable dose of olanzapine. And that aripiprazole was well tolerated.
Combined olanzapine and aripiprazole treated rat group showed significant decrease in, liver enzymes and serum bilirubin level when compared to olanzapine treated rats (Table 3 ). Olanzapine treated rats had more significant increase in liver enzymes and serum bilirubin level when compared to control group and aripeprazole treated rats. This is in line with Gonzalez et al. [87] and Ozcanli et al. [88] . Atypical antipsychotic drugs commonly cause asymptomatic increase in the liver enzymes and serum bilirubin levels, but rarely cause serious hepatotoxicity [89] . There exists a single study on olanzapine-induced hepatotoxicity supplemented with the histopathological findings that reported no damage to the general architecture of liver except to hepatocytes at cellular level, using doses of 2 and 4 mg/kg/d i.p for six weeks [90] . Liver enzymes elevation has been, however, reported extensively, but asymptomatic and returned to normal when the drug was discontinued [87] [88] . On the other hand, Gomez and colleagues studied more than 2000 patients treated with olanzapine who exhibited no symptoms of jaundice or clinical hepatitis at six month follow-up [10] .
The association of Non-Alcoholic fatty liver disease [NAFLD] , and metabolic syndrome [MetS] has been previously reported [91] . Occupational Diseases and Environmental Medicine
The importance of linking olanzapine, metabolic syndrome and liver steatosis came from the recent finding of Ballestri et al. [20] that, NAFLD is considered the hepatic manifestation of metabolic syndrome [MetS] . Histological examination of liver in control group (Figure 1) shows the maintenance of normal lobular architecture, normal histology. Histopathological finding in olanzapine treated rat group (Figure 3 ) in the present study showed a picture of non-alcoholic liver disease in the form of ballooning degeneration, inflammatory infiltrates and accumulated lipid vacuoles in hepatocytes [steatosis] [8 rats] . Steatosis was predominantly microvesicular and found in more than 50% of the lobules. Many Kupffer cells were also present. It had larger total fat cell areas than the control. There was no significant portal inflammation or hepatocytes damage at aripeprazole treated rats (Figure 2 ). And the portal tract showed small aggregates of chronic inflammatory cells.Combined olanzapineand aripiprazole-treated rats (Figure 4) showed less prominent and less severe picture of non-alcoholic liver disease [3 rats] compared to olanzapine treated rats [8 rats].
In a study by Chakrakodi et al. [92] , they examined the effect of aripiprazole in therapeutic dose [TD] and maximum therapeutic dose [MTD] for a period of 8 weeks on the liver histopathology of adult Sprague-Dawley rats. There was no significant portal inflammation or hepatocytes damage at TD, but at MTD, the portal tract showed small aggregates of chronic inflammatory cells.
Soliman et al. [93] compared liver histopathological changes in adult male albino rats treated with either olanzapine or aripiprazole for 14 weeks. They found histopathological changes in the liver in the form of non-alcoholic fatty liver disease in both olanzapine treated group and aripiprazole treated group. And that, these changes were more prominent and severe in olanzapine treated group than in aripiprazole treated group.
There was a trend towards an association between NASH and metabolic syndrome; in addition, patients with NAFLD with MetS were more likely to have severe steatosis and portal inflammation on liver biopsy [94] . Non-alcoholic steatohepatitis [NASH] , which is recognized as a progressive form of fatty liver disease, has been documented to have the potential to progress to cirrhosis and hepatocellular carcinoma [21] [22].
Conclusions and Recommendation
Olanzapine treatment was found to be associated with risk factors of metabolic syndrome clinically and experimentally and its hepatic manifestation of nonalcoholic fatty liver disease in wister rats. These represent major challenges in the treatment of schizophrenic patients, as they reduce compliance and contribute to increased cardiovascular and hepatic morbidity among patients especially our vulnerable hepatically and metabolically Egyptian patients.
Screening for and trying to minimize risk factors [including antipsychotic medication choice and use] should be a key priority in the multidisciplinary treatment of people with schizophrenia. Schizophrenic patients on olanzapine therapy must be followed regularly regarding metabolic parameters, hepatic, cardiac and cerebrovascular morbidity, with urgent interference with early manifestations. It is recommended to check liver enzymes regularly for those patients kept on atypical antipsychotic drug [olanzapine] . It is also important not to ignore the signs of liver damage if one is currently taking olanzapine and signs such as jaundice, abdominal pain or discomfort should not be taken lightly while taking olanzapine.
The addition of aripiprazole in olanzapine-treated subjects with schizophrenia was well tolerated and did not result in a change of psychiatric symptoms. Improvements were observed clinically and experimentally on measurements that predict medical morbidity and mortality, including weight, fasting blood glucose, triglycerides and non-alcoholic fatty liver changes in rats.
